- Types of Eczema
- Eczema in Children
- Living Well
- Eczema Products
- Get Involved
- For Medical Professionals
Historically, pediatric atopic dermatitis patients have been excluded from the early stages of the drug development process, but this soon may change.
A large-scale study conducted in the United Kingdom concluded that people with severe atopic dermatitis may be at an increased risk for cardiovascular disease.
Research studies reveal that people with atopic dermatitis are more likely to harbor suicidal thoughts than those without the disease.
In the “Golden Age of Eczema,” people with atopic dermatitis have more treatment options than ever before, with even more drugs making their way to pharmacy shelves.
Research reveals children with atopic dermatitis under age 2 are at greater risk for asthma and allergies.
New evidence shows that Lactobacillus-containing probiotic strains may reduce disease severity in children age 3 and under.
Dermatologists discuss the potential efficacy of prescribing an opioid antagonist to address the problem of itch in atopic dermatitis.
A new, nonsteroidal topical cream for AD called Jakafi (ruxolitinib) may soon hit pharmacy shelves.
Does atopic dermatitis behave differently based on a person’s skin tone? Researchers at the University of Amsterdam are trying to find out.
Off-label use of biologic treatments for atopic dermatitis may double the risk for serious infection compared to systemic treatments, researchers found.